Athenex

Athenex R&D per Employee

Delisted

The R&D Spending per Employee of Athenex (ATNX) as of Oct 24, 2026 is 87,281.62 USD. In the previous year, R&D Spending per Employee was 135,239.46 USD — a change of -35.46% (lower).

R&D per Employee

87,281.62USD

YoY

-35.46%

Last updated:

R&D Spending per Employee of Athenex is 2022 87,281.62 USD. R&D Spending per Employee of Athenex was 2021 135,239.46 USD. It decreases by -35.46% lower compared to the previous year.

The Athenex R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2015
41,252.95 USD
Jan 1, 2016
102,232.72 USD
Jan 1, 2017
129,505.90 USD
Jan 1, 2018
202,200.67 USD
Jan 1, 2019
142,315.35 USD
Jan 1, 2020
128,000.00 USD
Jan 1, 2021
135,239.46 USD
Jan 1, 2022
87,281.62 USD
The Athenex R&D per Employee history
YEARR&D per EmployeeYoY
87,281.62USD-35.46%
135,239.46USD+5.66%
128,000.00USD-10.06%
142,315.35USD-29.62%
202,200.67USD+56.13%
129,505.90USD+26.68%
102,232.72USD+147.82%
41,252.95USD+1,186.17%
3,207.42USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athenex Stock analysis

What does Athenex do? Athenex Inc was founded in 2003 and is headquartered in Buffalo, New York. The company specializes in the development and marketing of innovative drugs and therapies for the treatment of cancer and other serious diseases. Athenex's business model is based on collaboration with other companies and research institutions. The company works closely with academic partners to identify and develop new technologies and active ingredients. Athenex has also entered into several collaboration agreements with major pharmaceutical companies to facilitate the marketing of its products. The company has multiple divisions: Athenex Pharmaceutical Division, Athenex Oncology Division, and Athenex Pharmaceutical Technology Division. The Athenex Pharmaceutical Division focuses on the development and marketing of drugs for the treatment of cancer and other serious illnesses. The company has several promising drug candidates in its pipeline, including Oratopo, a drug for the treatment of breast cancer, and KX-2-391, a drug for the treatment of prostate cancer. The Athenex Oncology Division focuses on the development and marketing of innovative cancer treatment methods. The company has several promising therapy approaches in its pipeline, including an immunological cancer treatment based on activating the immune system to fight cancer cells. The Athenex Pharmaceutical Technology Division utilizes advanced technologies to improve the effectiveness and tolerability of drugs, including novel drug delivery systems and innovative packaging forms. Athenex also offers a wide range of products and services for the pharmaceutical industry, including drug development and manufacturing, as well as the supply of active ingredients and excipients. Overall, Athenex has a broad and interesting business model and a promising portfolio of drug candidates and therapy approaches in its pipeline. The company has also established strong partnerships with other companies and research institutions to advance its development and marketing of drugs and therapies. Athenex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athenex stock

R&D Spending per Employee of Athenex is 87,281.62 USD in 2022.

R&D Spending per Employee of Athenex changed from 135,239.46 USD to 87,281.62 USD, representing a -35.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Athenex since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Athenex historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Athenex

All Key Metrics — Athenex